The Experiences of People Who Live With Glanzmanns NCT05315232

Clinical Trial Details — Status: Completed

To understand the lived experiences of people with Glanzmanns Thrombasthenia

A qualitative study of people with Glanzmanns Thrombasthenia including an on-line survey, qualitative in-depth interviews and bleed diary completion.

Recruitment information / eligibility
Status	Completed
Enrollment	122
Est. completion date	April 27, 2023
Est. primary completion date	April 27, 2023
Accepts healthy volunteers	No
Gender	All
Age group	0 Years to 100 Years
Eligibility	Inclusion Criteria: Clinical diagnosis of congenital (inherited) Glanzmanns Thrombasthenia Exclusion Criteria: Acquired Glanzmanns Thrombasthenia

Other:
• survey and interview
qualitative assessment

Locations
Country	Name	City	State
United Kingdom	Oxford University Hospitals NHS Foundation Trust	Oxford	Oxfordshire

Sponsors *(2)*
Lead Sponsor	Collaborator
Haemnet	Hemab ApS

United Kingdom,

Outcome
Type	Measure	Description	Time frame
Primary	to understand the impact of GT on quality of life of affected individuals and their families.	Incidence of reported impact of GT on daily life using validated questionnaires EQ5D, MIQ, PHQ9, Rosenbergs self esteem scale.	one year
Secondary	Identify levels of acceptability of current treatments and management approaches	Rate of reported satisfaction with current treatments using self efficacy to manage disease assessment tool	one year
Secondary	Identify areas of unmet need among people with GT	Rate of reported unmet need using ED5D and MIQ	one year

See also
Status	Clinical Trial	Phase
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00230165` - The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Recruiting	`NCT02179359` - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	N/A
Recruiting	`NCT04119908` - Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases	N/A
Terminated	`NCT04548791` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders	Phase 1/Phase 2
Not yet recruiting	`NCT06204042` - Multinational Glanzmann Study
Completed	`NCT04595617` - Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	N/A
Completed	`NCT01917708` - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases	Phase 1
Active, not recruiting	`NCT03333486` - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Phase 2
Recruiting	`NCT06211634` - A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia	Phase 1/Phase 2
Completed	`NCT06234813` - Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study	N/A